Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 1,407 | 170 | 38 | 220 | 271 |
| Gross Profit | 1,407 | 169 | 38 | 220 | 271 |
| Operating Expenses | 4,032 | 1,371 | 701 | 634 | 811 |
| Operating Income | -2,625 | -1,201 | -664 | -414 | -540 |
| Interest Expense | 12 | 7 | 7 | 8 | 7 |
| Other Income | 0 | 1 | 0 | 0 | 0 |
| Pre-tax Income | -2,637 | -1,208 | -671 | -422 | -547 |
| Net Income Continuous | -2,637 | -1,208 | -671 | -422 | -547 |
| Net Income | $-2,637 | $-1,208 | $-671 | $-422 | $-547 |
| EPS Basic Total Ops | -1.56 | -0.90 | -0.48 | -0.30 | -0.42 |
| EPS Basic Continuous Ops | -1.57 | -0.87 | -0.49 | -0.31 | -0.40 |
| EPS Diluted Total Ops | -1.56 | -0.90 | -0.48 | -0.30 | -0.42 |
| EPS Diluted Continuous Ops | -1.57 | -0.87 | -0.49 | -0.31 | -0.40 |
| EBITDA(a) | $-2,625 | $-1,201 | $-664 | $-414 | $-540 |